Detailed Research on Atopic Dermatitis - Pipeline Review, H1 2017
Atopic Dermatitis - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
Complete report available @ Atopic Dermatitis - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 40, 21, 1, 44, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 2 and 2 molecules, respectively.
Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc Accolade Pharmaceuticals LLC Albireo Pharma Inc Almirall SA Amgen Inc Amorepacific Corp AnaptysBio Inc AnGes MG Inc Antibiotx ApS Avexxin AS Blueberry Therapeutics Ltd Brickell Biotech Inc Celgene Corp Cell Medica Ltd Cellceutix Corp ChemoCentryx Inc ChironWells GmbH Chugai Pharmaceutical Co Ltd Clevexel Pharma SA Curapel Ltd Cutanea Life Sciences Inc Dermala Inc Dr. August Wolff GmbH & Co KG Arzneimittle Eli Lilly and Company Exicure Inc F. Hoffmann-La Roche Ltd Foamix Pharmaceuticals Ltd Fountain Biopharma Inc Galapagos NV Galectin Therapeutics Inc GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Grupo Ferrer Internacional SA GTx Inc Han Wha Pharma Co Ltd HanAll Biopharma Co Ltd Heptares Therapeutics Ltd Herantis Pharma Plc iCo Therapeutics Inc. Immune Pharmaceuticals Inc Incyte Corp Inflamalps SA Japan Tobacco Inc Kang Stem Biotech Co Ltd KPI Therapeutics Inc LEO Pharma A/S Madam Therapeutics BV MedImmune LLC NeoPharm Co Ltd Novan Inc Novartis AG Orbis Biosciences Inc Otsuka Holdings Co Ltd Oxagen Ltd Pfizer Inc Pharis Biotec GmbH Pharmedartis GmbH Provectus Biopharmaceuticals Inc Qurient Co Ltd Realm Therapeutics Plc Regeneron Pharmaceuticals Inc Roivant Sciences Ltd Signum Biosciences Inc Signum Dermalogix Inc Spherium Biomed SL sterna biologicals Gmbh & Co KG Sun Pharma Advanced Research Company Ltd SWITCH Biotech LLC Thesan Pharmaceuticals Inc Torrent Pharmaceuticals Ltd Trevi Therapeutics Inc Valeant Pharmaceuticals International Inc Vicore Pharma AB Vitae Pharmaceuticals Inc VivaCell Biotechnology Espana SL Xencor Inc Zhejiang I-Biological Technology Co Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 03:28
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home